Rapid Dose Therapeutics Corp. (CSE:DOSE)
Canada · Delayed Price · Currency is CAD 0.0900
0.00 (0.00%)
Aug 7, 2026, 5:22 PM EST
Rapid Dose Therapeutics Balance Sheet
Financials in millions CAD. Fiscal year is March - February.
Millions CAD. Fiscal year is Mar - Feb.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Cash & Equivalents | 0.01 | 0.01 | 0.02 | 0.16 | 0.03 | 0.03 |
Cash & Short-Term Investments | 0.01 | 0.01 | 0.02 | 0.16 | 0.03 | 0.03 |
Cash Growth | -79.79% | -44.23% | -87.14% | 483.82% | -19.90% | -50.98% |
Accounts Receivable | 0.03 | 0.1 | 0.14 | 0.03 | 0.06 | 0.07 |
Other Receivables | 0.09 | 0.07 | 0.16 | 0.19 | 0.09 | 0.11 |
Receivables | 0.12 | 0.17 | 0.3 | 0.22 | 0.15 | 0.18 |
Inventory | 0.16 | 0.16 | 0.26 | 0.17 | 0.16 | 0.28 |
Prepaid Expenses | 0.04 | 0.02 | 0.06 | 0.1 | 0.06 | 0.09 |
Other Current Assets | - | - | 0.03 | 0.03 | 0.03 | 0.03 |
Total Current Assets | 0.32 | 0.36 | 0.66 | 0.68 | 0.42 | 0.61 |
Property, Plant & Equipment | 2.73 | 2.85 | 0.97 | 1.21 | 1.83 | 2.45 |
Other Long-Term Assets | 0.06 | 0.06 | - | - | - | - |
Total Assets | 3.12 | 3.28 | 1.63 | 1.89 | 2.25 | 3.07 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Accounts Payable | 2.29 | 2.15 | 1.94 | 1.12 | 2.78 | 1.36 |
Accrued Expenses | 2.56 | 2.53 | 2.29 | 1.47 | - | - |
Short-Term Debt | 3.61 | 3.07 | 2.61 | 0.21 | 1.57 | 0.76 |
Current Portion of Long-Term Debt | - | - | - | 0.09 | 0.19 | - |
Current Portion of Leases | 0.25 | 0.23 | - | 0.03 | 0.34 | 0.31 |
Current Unearned Revenue | - | - | - | - | 0.01 | 0.02 |
Other Current Liabilities | - | 0.46 | - | - | - | - |
Total Current Liabilities | 8.72 | 8.44 | 6.84 | 2.92 | 4.89 | 2.45 |
Long-Term Debt | - | - | - | 2.12 | - | - |
Long-Term Leases | 1.95 | 2.01 | - | - | 0.03 | 0.36 |
Total Liabilities | 10.66 | 10.46 | 6.84 | 5.04 | 4.92 | 2.82 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Common Stock | 29.42 | 29.28 | 28.26 | 26.61 | 25.13 | 25 |
Additional Paid-In Capital | 7 | 7 | 6.65 | 5.24 | 4.85 | 4.15 |
Retained Earnings | -48.49 | -47.99 | -44.6 | -39.26 | -34.97 | -31.16 |
Comprehensive Income & Other | 4.53 | 4.53 | 4.49 | 4.24 | 2.32 | 2.26 |
Shareholders' Equity | -7.54 | -7.18 | -5.21 | -3.16 | -2.67 | 0.25 |
Total Liabilities & Equity | 3.12 | 3.28 | 1.63 | 1.89 | 2.25 | 3.07 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Total Debt | 5.81 | 5.32 | 2.61 | 2.45 | 2.12 | 1.43 |
Net Cash (Debt) | -5.79 | -5.31 | -2.59 | -2.29 | -2.1 | -1.4 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.04 | -0.04 | -0.02 | -0.02 | -0.02 | -0.01 |
Filing Date Shares Outstanding | 136.44 | 135.18 | 129.53 | 122.3 | 103.57 | 103.07 |
Total Common Shares Outstanding | 136.44 | 135.18 | 129.53 | 117.81 | 103.57 | 103.07 |
Working Capital | -8.39 | -8.08 | -6.18 | -2.24 | -4.47 | -1.84 |
Book Value Per Share | -0.06 | -0.05 | -0.04 | -0.03 | -0.03 | 0.00 |
Tangible Book Value | -7.54 | -7.18 | -5.21 | -3.16 | -2.67 | 0.25 |
Tangible Book Value Per Share | -0.06 | -0.05 | -0.04 | -0.03 | -0.03 | 0.00 |
Machinery | 2.4 | 2.4 | 2.4 | 2.39 | 2.39 | 2.39 |